½ÃÀ庸°í¼­
»óǰÄÚµå
1301071

·Õ¸®µå ½ÃÄö½º ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼­ : Á¦Ç°º°, ±â¼úº°, ¿öÅ©Ç÷ο캰, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)

Long Read Sequencing Market Size, Share & Trends Analysis Report By Product, By Technology (Nanopore Sequencing), By Workflow, By Application, By End-Use, By Region And Segment Forecasts, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 180 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

·Õ¸®µå ½ÃÄö½º ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ·Õ¸®µå ½ÃÄö½º ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 37¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç CAGRÀº 30.92%¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÄö½Ì ¹æ¹ýÀº ÀǾàǰ º¯Çü¿¡ ÀÖ¾î °¡Àå Áß¿äÇÑ °ÍÀ¸·Î ³ªÅ¸³µÀ¸¸ç, ·Õ¸®µå ½ÃÄö½º Áö½ÄÀÇ È®´ë´Â ´©ÀûµÈ ½ÃÀå °¡Ä¡¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ±¸Á¶Àû º¯ÀÌ ºÐ¼®¿¡ ÀÌ·¯ÇÑ ±â¼úÀ» äÅÃÇÏ´Â »ç·Ê°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÇöÀç ¸¹Àº ¿¬±¸°¡ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â Á¦Á¶¾÷ü°¡ »õ·Ó°í Áøº¸µÈ ·Õ¸®µå ½ÃÄö½º¸¦ °³¹ßÇÒ ¶§ ¾à°£ À¯¸®ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ·Õ¸®µå ½ÃÄö½º ½ÃÀå¿¡¼­ ´Ù¸¥ ¸¹Àº Àü¸ÁÀ» ¿­ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÇöÀç ÁøÇà ÁßÀÎ COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ÁÖ¿ä ±â¾÷µéÀº Àü ¼¼°è °øÁß º¸°Ç ¿¬±¸¼Ò ¹× ¿¬±¸ÀÚµé°ú Çù·ÂÇÏ¿© ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º SARS-CoV-2ÀÇ ½Å¼ÓÇÑ ½ÃÄö½ÌÀ» ÅëÇØ ÇöÀç COVID-19 ÆÒµ¥¹ÍÀ» Áö¿øÇϰí ÀÖ½À´Ï´Ù.

°¢ ¾÷üµéÀº ¶ÇÇÑ »ùÇÃÀÇ ´Ù¾çÇÑ º´¿ø±ÕÀ» Ư¼ºÈ­Çϱâ À§ÇÑ ¿öÅ©Ç÷ο츦 °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù Oxford Nanopore Technologies´Â SARS-CoV-2¸¦ °ËÃâÇÒ ¼ö ÀÖ´Â È®Àå °¡´ÉÇÑ Àúºñ¿ëÀÇ ½Å¼ÓÇÑ ºÐ¼®¹ýÀÎ LamPORE¸¦ °³¹ßÇß½À´Ï´Ù. À¯ÀüÀÚ ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ·Õ¸®µå ½ÃÄö½Ì ±â¼ú¿¡ ´ëÇÑ »óÀ§ Á¦Á¶¾÷üÀÇ R&D ºñ¿ë Áõ°¡¿Í ÇÔ²² ÀÌ »ê¾÷Àº Å©°Ô ¹ßÀüÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ·Õ¸®µå ±â¼úÀº ÁÖ·Î Áúº´ À¯ÀüÀÚÁ°¡ ¾Ë·ÁÁ³°Å³ª ÀǽɵǴ À¯Àü¼º ÁúȯÀ» ¿¬±¸ÇÏ´Â µ¥ ÁÖ·Î »ç¿ëµË´Ï´Ù.

¶ÇÇÑ, Â÷¼¼´ë ½ÃÄö¼­¸¦ ±â¹ÝÀ¸·Î ÇÑ ÀÓ»ó Áúȯ ¿¬±¸ÀÇ ÇѰè´Â ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ ºÎºÐÀûÀ¸·Î ±Øº¹ÇÒ ¼ö ÀÖÀ¸¸ç, DNA 1ºÐÀÚ¿¡¼­ ´õ ±ä ¸®µå°¡ »ç¿ëµÇ±â ¶§¹®¿¡ ·Õ¸®µå ½ÃÄö½Ì ¹æ¹ýÀº ´Ù¸¥ ±â¼úº¸´Ù ºÐ¸íÈ÷ À¯¸®ÇÕ´Ï´Ù. ½ÃÀå È®´ëÀÇ ¶Ç ´Ù¸¥ ÃËÁø¿äÀÎÀº ÀÇ·á Áø´ÜÀ» À§ÇÑ Çö´ëÀû ¹æ¹ýÀÌ Á¡Á¡ ´õ ¸¹ÀÌ ¼ö¿ëµÇ°í ÀÖÀ¸¸ç, LRS ±â¼úÀÇ È޴뼺°ú ½Ç½Ã°£ ¼Óµµ´Â ¼ö¿ä Áõ°¡ÀÇ ¶Ç ´Ù¸¥ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¿°»öü Á߽ɺÎÀÇ Á¤È®ÇÑ ÂüÁ¶ Áöµµ¸¦ ÀÛ¼ºÇÏ´Â µ¥¿¡µµ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¹Àº »ý¸í°øÇÐ ±â¾÷µéÀÌ ¶óÀ̺귯¸® Áغñ¿¡ ´ëÇÑ »õ·Î¿î Á¢±Ù ¹æ½Ä°ú À¯Àüü ºÐ¼®À» À§ÇÑ µµ±¸¸¦ °áÇÕÇÑ ÃÖ÷´Ü ±â¼úÀ» °³¹ßÇϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ¸¹Àº ¿¬±¸ °á°ú¿¡ µû¸£¸é, LRS ±â¼úÀº À¯ÀüÀû ±â¿øÀÌ ºÒºÐ¸íÇÑ Àΰ£ Áúº´¿¡¼­ »õ·Î¿î À¯ÇØÇÑ µ¹¿¬º¯À̸¦ ½Äº°ÇÏ´Â µ¥ ¸Å¿ì À¯¿ëÇÏ´Ù´Â °ÍÀÌ ¹àÇôÁ³½À´Ï´Ù. ÀÌ´Â ¿¬±¸ÀÚµéÀÌ ÀüÀå À¯Àüü ¿°±â¼­¿­ ºÐ¼®(WGS) ±â¼úÀ» Ȱ¿ëÇÏ¿© À¯Àü ÀÇÇÐÀÇ ¹ßÀüÀ» À§ÇÑ ´Ù¾çÇÑ °¡´É¼ºÀ» Á¦°øÇϰí ÀÖ½À´Ï´Ù.

·Õ¸®µå ½ÃÄö½º ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • ±â¼úº°·Î´Â ´ÜÀÏ ºÐÀÚ ½Ç½Ã°£ ½ÃÄö½Ì(SMRT)ÀÌ 2021³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ÀÌ ±â¼úÀº ù »ó¾÷Àû Ãâ½Ã ÀÌÈÄ ´Ù¾çÇÑ ÀÀ¿ë ºÐ¾ß¿¡¼­ Àü¹®°¡µé »çÀÌ¿¡¼­ Àα⸦ ¾ò°í ÀÖ½À´Ï´Ù.
  • Á¦Ç°º°·Î´Â 2022³â ¼Ò¸ðǰ ºÎ¹®ÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ½Ã¾à ¹× ŰƮ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù.
  • ¿ëµµº°·Î´Â ¾Ï ºÐ¾ß°¡ 2022³â °¡Àå ³ôÀº Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ¾Ï »ý¹°ÇÐ ºÐ¾ß¿¡¼­ÀÇ LRS äÅà Áõ°¡°¡ ÀÌ ºÎ¹® ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¿öÅ©Ç÷ο캰·Î º¸¸é ½ÃÄö½ÌÀÌ 2022³â ÀÌ ºÎ¹®À» Áö¹èÇß½À´Ï´Ù. À¯ÀüüÇÐ ºÐ¾ßÀÇ ¿¬±¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¼¼°è ½ÃÀå¿¡¼­ ½ÃÄö½Ì ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
  • ÃÖÁ¾ ¿ëµµº°·Î´Â Çмú ¿¬±¸°¡ 2022³â Å« ºñÁßÀ» Â÷ÁöÇß½À´Ï´Ù. À¯ÀüüÇÐ ¹æ¹ý·ÐÀ» ޱ¸ÇÏ´Â ¸¹Àº »ý¸í°øÇÐ ¿¬±¸±â°üÀÌ Á¸ÀçÇÑ´Ù´Â Á¡ÀÌ ÀÌ ºÐ¾ßÀÇ ¼öÀÍ Ã¢ÃâÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ºÏ¹Ì Áö¿ªÀº ´Ü¹éÁúÇÐ, À¯ÀüüÇÐ, Á¾¾çÇÐ, Áø´Ü °Ë»ç ºÐ¾ß¿¡¼­ ¸í¼ºÀÌ ³ô¾Æ 2022³â ¼¼°è ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ÁÖ¿ä ±â¾÷µéÀÇ Áö¼ÓÀûÀÎ Á¦Ç° °³¼± ³ë·Âµµ ºÏ¹Ì ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ¾Æ½Ã¾Æ ±¹°¡µéÀÇ ÁÖ¿ä ¾÷üµéÀÇ Ä§Åõ¿Í ÁÖ¿ä ¾÷üµéÀÇ ÀÌ ºÐ¾ß¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

  • ½ÃÀå ¼¼ºÐÈ­¿Í ¹üÀ§
  • ½ÃÀå Á¤ÀÇ
    • Á¤º¸ ºÐ¼®
    • ½ÃÀå Çü¼º°ú µ¥ÀÌÅÍ ½Ã°¢È­
    • µ¥ÀÌÅÍ °ËÁõ°ú °ø°³
  • Á¶»ç °¡Á¤
  • Á¤º¸ Á¶´Þ
    • 1Â÷ Á¶»ç
  • Á¤º¸ ¶Ç´Â µ¥ÀÌÅÍ ºÐ¼®
  • ½ÃÀå Çü¼º°ú °ËÁõ
  • ½ÃÀå ¸ðµ¨
  • ¼¼°è ½ÃÀå : CAGR °è»ê
  • ¸ñÀû

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇöȲ
  • ºÎ¹® ÇöȲ
  • °æÀï »óȲ ÇöȲ

Á¦3Àå ½ÃÀå º¯¼ö, µ¿Çâ ¹× ¹üÀ§

  • ½ÃÀå °èÅë Àü¸Á
    • »óºÎ ½ÃÀå Àü¸Á
    • °ü·Ã/º¸Á¶ÀûÀÎ ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • ¾÷°è ºÐ¼® Åø
    • Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
    • COVID-19 °¨¿°ÁõÀÇ ¿µÇ⠺м®

Á¦4Àå Á¦Ç° ºñÁö´Ï½º ºÐ¼®

  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : Á¦Ç° º¯µ¿ ºÐ¼®
  • ±â±â
  • ¼Ò¸ðǰ
  • ¼­ºñ½º

Á¦5Àå ±â¼ú ºñÁö´Ï½º ºÐ¼®

  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ±â¼ú º¯µ¿ ºÐ¼®
  • ´ÜÀÏ ºÐÀÚ ½Ç½Ã°£ ½ÃÄö½Ì
  • ³ª³ëÆ÷¾î ½ÃÄö½Ì
  • ±âŸ

Á¦6Àå ¿öÅ©ÇÃ·Î¿ì ºñÁö´Ï½º ºÐ¼®

  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ¿öÅ©ÇÃ·Î¿ì º¯µ¿ ºÐ¼®
  • ÇÁ¸® ½ÃÄö½Ì
  • ½ÃÄö½Ì
  • µ¥ÀÌÅÍ ºÐ¼®

Á¦7Àå ¿ëµµ ºñÁö´Ï½º ºÐ¼®

  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • Àü°Ô³ð ¹è¿­ °áÁ¤
  • Ÿ°Ù ½ÃÄö½Ì
  • ¸ÞŸÀ¯ÀüüÇÐ
  • RNA ½ÃÄö½Ì
  • ¿¡ÇÇÁ¦³×ƽ½º
  • ±âŸ

Á¦8Àå ÃÖÁ¾ ¿ëµµ ºñÁö´Ï½º ºÐ¼®

  • ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµ º¯µ¿ ºÐ¼®
  • Çмú¿¬±¸±â°ü
  • º´¿ø°ú Ŭ¸®´Ð
  • Á¦¾à ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ

Á¦9Àå Áö¿ª ºñÁö´Ï½º ºÐ¼®

  • Áö¿ªº° : ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå Á¡À¯À², 2022³â ¹× 2030³â
  • ºÏ¹Ì
    • ºÏ¹ÌÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå, 2018-2030³â
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • À¯·´ÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå, 2018-2030³â
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • µ§¸¶Å©
    • ½º¿þµ§
    • ³ë¸£¿þÀÌ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå, 2018-2030³â
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ű¹
    • Çѱ¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå, 2018-2030³â
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
  • MEA
    • MEA ·Õ¸®µå ½ÃÄö½Ì ½ÃÀå, 2018-2030³â
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • Äí¿þÀÌÆ®

Á¦10Àå °æÀï »óȲ

  • ±â¾÷ ºÐ·ù
  • Àü·« ¸ÅÇÎ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2022³â
  • ±â¾÷ °³¿ä¡¤¸®½ºÆ®
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies Limited
    • Quantapore, Inc.
    • Element Biosciences
    • BGI Genomics
    • Eurofins Genomics
    • Stratos Genomics, Inc.
    • MicrobesNG
    • NextOmics
    • New England Biolabs
ksm 23.07.21

Long Read Sequencing Market Growth & Trends

The global long read sequencing market size is expected to reach USD 3.78 billion by 2030, registering a CAGR of 30.92% according to a new report by Grand View Research, Inc. Since the sequencing method has shown to be of utmost importance in modifying pharmaceuticals, there is also a cumulative market value for the expanding knowledge of long read sequencing. An increase in the adoption of these technologies for the analysis of structural variants is expected to drive the market throughout the forecast period.

Currently, a lot of research is being conducted which is forecast to give manufacturers a slight advantage as they develop new and advanced elongated read sequencing, as well as to open up a lot of other prospects in the long read sequencing market. Furthermore, owing to the ongoing COVID-19 pandemic, key players are working with public health laboratories and researchers around the world to support the current COVID-19 pandemic by rapid sequencing of the novel coronavirus SARS-CoV-2.

Companies are also involved in the development of workflows to characterize a wide range of pathogens in a sample. Recently, Oxford Nanopore Technologies developed LamPORE-a scalable, low-cost, rapid assay for the detection of SARS-CoV-2. A rise in the prevalence of genetic disorders combined with an increase in top manufacturers' R&D expenditures in long-read sequencing technology is projected to greatly advance the industry. The long read technique is mostly used to study genetic disorders for which disease loci are either well-known or strongly suspected.

In addition, the limitations of clinical disease research based on next-generation sequencing could be partially overcome by these technologies. Since longer reads from a single DNA molecule are used, long-read sequencing methods have a distinct advantage over other technology. Another driver of market expansion is the rising acceptance of contemporary methods for medical diagnosis. The portability and real-time speed of LRS technology are further factors contributing to its rising demand.

It is additionally utilized to create a precise reference map of the chromosome centromere. In addition, numerous biotech firms are creating cutting-edge technologies that combine a fresh approach to library preparation with tools for genomic analysis. Accordingly, a number of researches show that LRS technology is quite useful for identifying novel harmful mutations in human disorders with unidentified genetic origins. This offers a wealth of potential for researchers to use whole-genome sequencing (WGS) technology to develop medical genetics.

Long Read Sequencing Market Report Highlights

  • By technology, Single Molecule Real Time Sequencing (SMRT) dominated the market in 2021. This technique is gaining traction among professionals for various applications since the first commercial launch
  • Based on products, the consumables segment accounted for the largest share in 2022. Increasing demand for reagents & kits has majorly driven the segment growth
  • By application, the cancer segment captured the highest share in 2022. Increasing adoption of LRS in the field of cancer biology is anticipated to be the major factor for the segment growth
  • By workflow, sequencing is the dominating segment in 2022. Increasing research in the genomics arena has resulted in growing demand for sequencing services in the global market
  • Based on the end-users, academic research accounted for a significant share in 2022. The presence of a large number of biotechnology institutes that explore genomics methodologies is expected to propel the segment revenue generation
  • North America dominated the global market in 2022 owing to the presence of well-established proteomics, genomics, oncology & diagnostic screening fields in the region
  • Continuous efforts by key players to improve their product offerings is also contributing to the North America's regional market growth
  • Asia Pacific is anticipated to witness the fastest growth throughout the forecast period. This can be attributed to the growing penetration of key players in Asian countries as well as increasing investments in this field by key players

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Information Analysis
    • 1.2.2. Market Formulation & Data Visualization
    • 1.2.3. Data Validation & Publishing
  • 1.3. Research Assumptions
  • 1.4. Information Procurement
    • 1.4.1. Primary Research
  • 1.5. Information or Data Analysis
  • 1.6. Market Formulation & Validation
  • 1.7. Market Model
  • 1.8. Global Market: CAGR Calculation
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advantages Offered By Long Read Sequencing Techniques
      • 3.2.1.2. Increasing Applications In Clinical Sequencing And Analysis
      • 3.2.1.3. Advancements In Data Analysis Platforms
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Error Rates Of Long Read Technologies
      • 3.2.2.2. Technological Challenges Associated With Long Read Techniques
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

  • 4.1. Long Read Sequencing Market: Product Movement Analysis
  • 4.2. Instruments
    • 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
  • 4.3. Consumables
    • 4.3.1. Consumables Market, 2018 - 2030 (USD Million)
  • 4.4. Services
    • 4.4.1. Services Market, 2018 - 2030 (USD Million)

Chapter 5. Technology Business Analysis

  • 5.1. Long Read Sequencing Market: Technology Movement Analysis
  • 5.2. Single Molecule Real Time Sequencing
    • 5.2.1. Single Molecule Real Time Sequencing Market, 2018 - 2030 (USD Million)
  • 5.3. Nanopore Sequencing
    • 5.3.1. Nanopore Sequencing Market, 2018 - 2030 (USD Million)
  • 5.4. Others
    • 5.4.1. Other Technologies Market, 2018 - 2030 (USD Million)

Chapter 6. Workflow Business Analysis

  • 6.1. Long Read Sequencing Market: Workflow Movement Analysis
  • 6.2. Pre-sequencing
    • 6.2.1. Pre-sequencing Market, 2018 - 2030 (USD Million)
  • 6.3. Sequencing
    • 6.3.1. Sequencing Market, 2018 - 2030 (USD Million)
  • 6.4. Data Analysis
    • 6.4.1. Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

  • 7.1. Long Read Sequencing Market: Application Movement Analysis
  • 7.2. Whole Genome Sequencing
    • 7.2.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
  • 7.3. Targeted Sequencing
    • 7.3.1. Targeted Sequencing Market, 2018 - 2030 (USD Million)
  • 7.4. Metagenomics
    • 7.4.1. Metagenomics Market, 2018 - 2030 (USD Million)
  • 7.5. RNA Sequencing
    • 7.5.1. RNA Sequencing Market, 2018 - 2030 (USD Million)
  • 7.6. Epigenetics
    • 7.6.1. Epigenetics Market, 2018 - 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Other Applications Market, 2018 - 2030 (USD Million)

Chapter 8. End-Use Business Analysis

  • 8.1. Long Read Sequencing Market: End-use Movement Analysis
  • 8.2. Academic & Research Institutes
    • 8.2.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
  • 8.3. Hospitals & Clinics
    • 8.3.1. Hospitals & Clinics Market, 2018 - 2030 (USD Million)
  • 8.4. Pharmaceutical & Biotechnology Companies
    • 8.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 8.5. Others
    • 8.5.1. Other End-uses Market, 2018 - 2030 (USD Million)

Chapter 9. Regional Business Analysis

  • 9.1. Long Read Sequencing Market Share By Region, 2022 & 2030
  • 9.2. North America
    • 9.2.1. North America Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.2.2. U.S.
      • 9.2.2.1. Key Country Dynamics
      • 9.2.2.2. Competitive Scenario
      • 9.2.2.3. Regulatory Framework
      • 9.2.2.4. U.S. Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.2.3. Canada
      • 9.2.3.1. Key Country Dynamics
      • 9.2.3.2. Competitive Scenario
      • 9.2.3.3. Regulatory Framework
      • 9.2.3.4. Canada Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.3. Europe
    • 9.3.1. Europe Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.2. UK
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Competitive Scenario
      • 9.3.2.3. Regulatory Framework
      • 9.3.2.4. UK Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.3. Germany
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Competitive Scenario
      • 9.3.3.3. Regulatory Framework
      • 9.3.3.4. Germany Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.4. France
      • 9.3.4.1. Key Country Dynamics
      • 9.3.4.2. Competitive Scenario
      • 9.3.4.3. Regulatory Framework
      • 9.3.4.4. France Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.5. Italy
      • 9.3.5.1. Key Country Dynamics
      • 9.3.5.2. Competitive Scenario
      • 9.3.5.3. Regulatory Framework
      • 9.3.5.4. Italy Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.6. Spain
      • 9.3.6.1. Key Country Dynamics
      • 9.3.6.2. Competitive Scenario
      • 9.3.6.3. Regulatory Framework
      • 9.3.6.4. Spain Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.7. Denmark
      • 9.3.7.1. Key Country Dynamics
      • 9.3.7.2. Competitive Scenario
      • 9.3.7.3. Regulatory Framework
      • 9.3.7.4. Denmark Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.8. Sweden
      • 9.3.8.1. Key Country Dynamics
      • 9.3.8.2. Competitive Scenario
      • 9.3.8.3. Regulatory Framework
      • 9.3.8.4. Sweden Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.3.9. Norway
      • 9.3.9.1. Key Country Dynamics
      • 9.3.9.2. Competitive Scenario
      • 9.3.9.3. Regulatory Framework
      • 9.3.9.4. Norway Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.4. Asia Pacific
    • 9.4.1. Asia Pacific Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.2. Japan
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Competitive Scenario
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Japan Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.3. China
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Competitive Scenario
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. China Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.4. India
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Competitive Scenario
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. India Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.5. Australia
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Competitive Scenario
      • 9.4.5.3. Regulatory Framework
      • 9.4.5.4. Australia Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.6. Thailand
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Competitive Scenario
      • 9.4.6.3. Regulatory Framework
      • 9.4.6.4. Thailand Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.4.7. South Korea
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Competitive Scenario
      • 9.4.7.3. Regulatory Framework
      • 9.4.7.4. South Korea Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.5. Latin America
    • 9.5.1. Latin America Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.2. Brazil
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Brazil Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.3. Mexico
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Competitive Scenario
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Mexico Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.5.4. Argentina
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Competitive Scenario
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Argentina Long Read Sequencing Market, 2018 - 2030 (USD Million)
  • 9.6. MEA
    • 9.6.1. MEA Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.6.2. South Africa
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. South Africa Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.6.3. Saudi Arabia
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Saudi Arabia Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.6.4. UAE
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Competitive Scenario
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. UAE Long Read Sequencing Market, 2018 - 2030 (USD Million)
    • 9.6.5. Kuwait
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Competitive Scenario
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Kuwait Long Read Sequencing Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Strategy Mapping
  • 10.3. Company Market Share Analysis, 2022
  • 10.4. Company Profiles/Listing
    • 10.4.1. Pacific Biosciences of California, Inc.
      • 10.4.1.1. Overview
      • 10.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.1.3. Product Benchmarking
      • 10.4.1.4. Strategic Initiatives
    • 10.4.2. Oxford Nanopore Technologies Limited
      • 10.4.2.1. Overview
      • 10.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.2.3. Product Benchmarking
      • 10.4.2.4. Strategic Initiatives
    • 10.4.3. Quantapore, Inc.
      • 10.4.3.1. Overview
      • 10.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.3.3. Product Benchmarking
      • 10.4.3.4. Strategic Initiatives
    • 10.4.4. Element Biosciences
      • 10.4.4.1. Overview
      • 10.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.4.3. Product Benchmarking
      • 10.4.4.4. Strategic Initiatives
    • 10.4.5. BGI Genomics
      • 10.4.5.1. Overview
      • 10.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.5.3. Product Benchmarking
      • 10.4.5.4. Strategic Initiatives
    • 10.4.6. Eurofins Genomics
      • 10.4.6.1. Overview
      • 10.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.6.3. Product Benchmarking
      • 10.4.6.4. Strategic Initiatives
    • 10.4.7. Stratos Genomics, Inc.
      • 10.4.7.1. Overview
      • 10.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.7.3. Product Benchmarking
      • 10.4.7.4. Strategic Initiatives
    • 10.4.8. MicrobesNG
      • 10.4.8.1. Overview
      • 10.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.8.3. Product Benchmarking
      • 10.4.8.4. Strategic Initiatives
    • 10.4.9. NextOmics
      • 10.4.9.1. Overview
      • 10.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.9.3. Product Benchmarking
      • 10.4.9.4. Strategic Initiatives
    • 10.4.10. New England Biolabs
      • 10.4.10.1. Overview
      • 10.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 10.4.10.3. Product Benchmarking
      • 10.4.10.4. Strategic Initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦